• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Menveo (meningitis vaccine)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Menveo (meningitis vaccine)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Menveo is a quadrivalent conjugated vaccine containing the Neisseria meningitidis serogroups A, C, Y and W-135. The presence of serum bactericidal antibodies protects against invasive meningococcal disease. Vaccination with Menveo leads to the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-135.

    Menveo is specifically indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. in persons 11 to 55 years of age.

    Menveo is supplied as a solution for intramuscular injection. Following reconstitution, Menveo should be administered as a single 0.5mL intramuscular injection, preferably into the deltoid muscle (upper arm).

    Clinical Results

    FDA Approval
    The FDA approval of Menveo was based on immunogenicity studies among subjects aged 11 to 55 years where efficay was inferred from the demonstration of non-inferiority of the serum bactericidal antibody responses to those of Menactra. A a randomized, multicenter, active controlled clinical trial conducted in the U.S. enrolled 3539 adolescent (11 to 18 years of age) and adult (19 to 55 years of age) subjects. The subjects were randomized to receive a dose of Menveo or Menactra. Sera were obtained both before vaccination and 28 days after vaccination. The primary effectiveness endpoints of the study were hSBA seroresponse rates to each serogroup 28 days after vaccination. The non-inferiority of Menveo to Menactra was demonstrated for all four serogroups using the primary endpoint (hSBA seroresponse) in both age populations.

    Side Effects

    Adverse events associated with the use of Menveo may include, but are not limited to, the following:

    • pain at the injection site
    • headache
    • myalgia
    • malaise
    • nausea

    Mechanism of Action

    Menveo is a quadrivalent conjugated vaccine containing the Neisseria meningitidis serogroups A, C, Y and W-135. The presence of serum bactericidal antibodies protects against invasive meningococcal disease. Vaccination with Menveo leads to the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-135.

    Additional Information

    For additional information regarding Menveo or invasive meningococcal disease, please visit the Menveo web page.

    Approval Date: 2010-02-01
    Company Name: Novartis
    Back to Listings

    Upcoming Events

    • 12Apr

      The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    • White House

      Trial Stakeholders Advise White House on Emergency Research Infrastructure

    • SurveywBlueBackground-360x240.png

      Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing